This review looked at why some patients with B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia do not respond well to CAR T-cell therapy. The researchers identified three main reasons for this resistance: factors within the tumor itself, problems with how the T-cells function, and a surrounding environment that suppresses the immune system.
To address these issues, the review highlights several potential strategies. These include designing T-cells that can target multiple markers at once, as well as changing the metabolism or genetics of the cells. They also looked at ways to change the tumor's local environment to make it more favorable for treatment.
Because this is a systematic review of existing literature rather than a new clinical trial, these findings are currently theoretical. While these strategies provide a roadmap for improving future treatments, they have not yet been tested in large-scale human trials to confirm their safety or effectiveness.
